{"id":1800,"date":"2022-02-14T10:00:02","date_gmt":"2022-02-14T09:00:02","guid":{"rendered":"https:\/\/www.fondazionebonadonna.eu\/?p=1800"},"modified":"2022-02-14T10:11:53","modified_gmt":"2022-02-14T09:11:53","slug":"dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer","status":"publish","type":"post","link":"https:\/\/www.fondazionebonadonna.eu\/en\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\/","title":{"rendered":"Dabrafenib and trametinib in anaplastic thyroid cancer"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_custom_heading text=&#8221;An updated analysis confirms the good safety profile and substantial clinical benefits with dabrafenib and trametinib in BRAF V600E\u2013mutant anaplastic thyroid cancer&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]A phase II study on BRAF V600E\u2013mutant anaplastic thyroid cancer patients confirms the benefit of the treatment with dabrafenib plus trametinib: beside a good safety and tolerability profile, relevant clinical benefits have been shown in patients with this rare and aggressive tumor.<\/p>\n<p>Data come from a basket study, the ROAR (Rare Oncology Agnostic Research) trial, that has been enrolling patients since 2014 in 27 cancer centers in 13 countries; patients share a common tumor characteristic \u2013 the BRAF v600E mutation \u2013 although they may have an array of different rare cancers. The updated analysis on anaplastic thyroid cancer, recently published on <a href=\"https:\/\/www.annalsofoncology.org\/article\/S0923-7534(22)00005-9\/fulltext\" target=\"_blank\" rel=\"noopener\">Annals of Oncology<\/a>, includes 4 years of additional study follow-up data from 36 patients treated with the BRAF inhibitor dabrafenib and MEK inhibitor trametinib, the only guideline-recommended systemic therapy option specifically approved by regulatory authorities worldwide since 2018 for the treatment of advanced BRAF V600E\u2013mutant anaplastic thyroid cancer. New data show a 56% overall response rate, including 3 complete responses; the 12-month duration of response rate was 50%. Median progression-free survival and overall survival were 6.7 and 14.5 months, respectively; 12-month progression-free survival and overall survival rates were 43.2% and 51.7%, and the 24-month overall survival rate was 31.5%, with adverse events consistent with the established tolerability profile of dabrafenib plus trametinib.<\/p>\n<p>Authors say that these updated results confirm the substantial clinical benefit and tolerability of dabrafenib plus trametinib in BRAF V600E\u2013mutant anaplastic thyroid cancer: the treatment notably improves long-term survival and thus represents a meaningful treatment option for patients with this rare, aggressive cancer.[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/2&#8243;][vc_single_image image=&#8221;1803&#8243; img_size=&#8221;large&#8221;][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_custom_heading text=&#8221;An updated analysis confirms the good safety profile and substantial clinical benefits with dabrafenib and trametinib in BRAF V600E\u2013mutant anaplastic thyroid cancer&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]A<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":2,"featured_media":1803,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39,21],"tags":[],"class_list":["post-1800","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dabrafenib and trametinib in anaplastic thyroid cancer - Fondazione Gianni Bonadonna<\/title>\n<meta name=\"description\" content=\"An updated analysis confirms the good safety profile and substantial clinical benefits with dabrafenib and trametinib in BRAF V600E\u2013mutant anaplastic thyroid cancer\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fondazionebonadonna.eu\/en\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dabrafenib and trametinib in anaplastic thyroid cancer - Fondazione Gianni Bonadonna\" \/>\n<meta property=\"og:description\" content=\"An updated analysis confirms the good safety profile and substantial clinical benefits with dabrafenib and trametinib in BRAF V600E\u2013mutant anaplastic thyroid cancer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fondazionebonadonna.eu\/en\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-14T09:00:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-02-14T09:11:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/01\/AdobeStock_259168782.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2500\" \/>\n\t<meta property=\"og:image:height\" content=\"1500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fondazione Gianni Bonadonna\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\\\/\"},\"author\":{\"name\":\"Fondazione Gianni Bonadonna\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"headline\":\"Dabrafenib and trametinib in anaplastic thyroid cancer\",\"datePublished\":\"2022-02-14T09:00:02+00:00\",\"dateModified\":\"2022-02-14T09:11:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\\\/\"},\"wordCount\":328,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/AdobeStock_259168782.jpg\",\"articleSection\":[\"Events\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\\\/\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\\\/\",\"name\":\"Dabrafenib and trametinib in anaplastic thyroid cancer - Fondazione Gianni Bonadonna\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/AdobeStock_259168782.jpg\",\"datePublished\":\"2022-02-14T09:00:02+00:00\",\"dateModified\":\"2022-02-14T09:11:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"description\":\"An updated analysis confirms the good safety profile and substantial clinical benefits with dabrafenib and trametinib in BRAF V600E\u2013mutant anaplastic thyroid cancer\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/AdobeStock_259168782.jpg\",\"contentUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/AdobeStock_259168782.jpg\",\"width\":2500,\"height\":1500},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dabrafenib and trametinib in anaplastic thyroid cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/\",\"name\":\"Fondazione Gianni Bonadonna\",\"description\":\"Fondazione Gianni Bonadonna\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\",\"name\":\"Fondazione Gianni Bonadonna\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"caption\":\"Fondazione Gianni Bonadonna\"},\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/author\\\/fgb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dabrafenib and trametinib in anaplastic thyroid cancer - Fondazione Gianni Bonadonna","description":"An updated analysis confirms the good safety profile and substantial clinical benefits with dabrafenib and trametinib in BRAF V600E\u2013mutant anaplastic thyroid cancer","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fondazionebonadonna.eu\/en\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Dabrafenib and trametinib in anaplastic thyroid cancer - Fondazione Gianni Bonadonna","og_description":"An updated analysis confirms the good safety profile and substantial clinical benefits with dabrafenib and trametinib in BRAF V600E\u2013mutant anaplastic thyroid cancer","og_url":"https:\/\/www.fondazionebonadonna.eu\/en\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\/","og_site_name":"Fondazione Gianni Bonadonna","article_published_time":"2022-02-14T09:00:02+00:00","article_modified_time":"2022-02-14T09:11:53+00:00","og_image":[{"width":2500,"height":1500,"url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/01\/AdobeStock_259168782.jpg","type":"image\/jpeg"}],"author":"Fondazione Gianni Bonadonna","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fondazione Gianni Bonadonna","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\/#article","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\/"},"author":{"name":"Fondazione Gianni Bonadonna","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"headline":"Dabrafenib and trametinib in anaplastic thyroid cancer","datePublished":"2022-02-14T09:00:02+00:00","dateModified":"2022-02-14T09:11:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\/"},"wordCount":328,"commentCount":0,"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/01\/AdobeStock_259168782.jpg","articleSection":["Events"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\/","url":"https:\/\/www.fondazionebonadonna.eu\/en\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\/","name":"Dabrafenib and trametinib in anaplastic thyroid cancer - Fondazione Gianni Bonadonna","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/01\/AdobeStock_259168782.jpg","datePublished":"2022-02-14T09:00:02+00:00","dateModified":"2022-02-14T09:11:53+00:00","author":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"description":"An updated analysis confirms the good safety profile and substantial clinical benefits with dabrafenib and trametinib in BRAF V600E\u2013mutant anaplastic thyroid cancer","breadcrumb":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fondazionebonadonna.eu\/en\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\/#primaryimage","url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/01\/AdobeStock_259168782.jpg","contentUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/01\/AdobeStock_259168782.jpg","width":2500,"height":1500},{"@type":"BreadcrumbList","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/dabrafenib-and-trametinib-in-anaplastic-thyroid-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fondazionebonadonna.eu\/en\/"},{"@type":"ListItem","position":2,"name":"Dabrafenib and trametinib in anaplastic thyroid cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.fondazionebonadonna.eu\/#website","url":"https:\/\/www.fondazionebonadonna.eu\/","name":"Fondazione Gianni Bonadonna","description":"Fondazione Gianni Bonadonna","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fondazionebonadonna.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146","name":"Fondazione Gianni Bonadonna","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","caption":"Fondazione Gianni Bonadonna"},"url":"https:\/\/www.fondazionebonadonna.eu\/en\/author\/fgb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/1800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/comments?post=1800"}],"version-history":[{"count":0,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/1800\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media\/1803"}],"wp:attachment":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media?parent=1800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/categories?post=1800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/tags?post=1800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}